AU2019300161B2 - Thrombin inhibitors, formulations, and uses thereof - Google Patents

Thrombin inhibitors, formulations, and uses thereof Download PDF

Info

Publication number
AU2019300161B2
AU2019300161B2 AU2019300161A AU2019300161A AU2019300161B2 AU 2019300161 B2 AU2019300161 B2 AU 2019300161B2 AU 2019300161 A AU2019300161 A AU 2019300161A AU 2019300161 A AU2019300161 A AU 2019300161A AU 2019300161 B2 AU2019300161 B2 AU 2019300161B2
Authority
AU
Australia
Prior art keywords
compound
disease
tablet
methyl
amorphous solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019300161A
Other languages
English (en)
Other versions
AU2019300161A1 (en
Inventor
Maria De Los Angeles Estiarte-Martinez
David Ben Kita
Kevin Michael Short
Nilantha Sudath Sirisoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verseon International Corp
Original Assignee
Verseon International Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseon International Corp filed Critical Verseon International Corp
Publication of AU2019300161A1 publication Critical patent/AU2019300161A1/en
Application granted granted Critical
Publication of AU2019300161B2 publication Critical patent/AU2019300161B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2019300161A 2018-07-13 2019-07-12 Thrombin inhibitors, formulations, and uses thereof Active AU2019300161B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697817P 2018-07-13 2018-07-13
US62/697,817 2018-07-13
PCT/US2019/041699 WO2020014669A1 (en) 2018-07-13 2019-07-12 Thrombin inhibitors, formulations, and uses thereof

Publications (2)

Publication Number Publication Date
AU2019300161A1 AU2019300161A1 (en) 2021-02-25
AU2019300161B2 true AU2019300161B2 (en) 2025-05-22

Family

ID=67470750

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019300161A Active AU2019300161B2 (en) 2018-07-13 2019-07-12 Thrombin inhibitors, formulations, and uses thereof

Country Status (13)

Country Link
US (1) US11865110B2 (enExample)
EP (1) EP3820564A1 (enExample)
JP (2) JP2021531338A (enExample)
KR (1) KR20210080347A (enExample)
CN (1) CN113164765B (enExample)
AU (1) AU2019300161B2 (enExample)
BR (1) BR112021000515A2 (enExample)
CA (1) CA3106359A1 (enExample)
IL (1) IL280078B2 (enExample)
MX (1) MX2021000472A (enExample)
SG (1) SG11202100247WA (enExample)
WO (1) WO2020014669A1 (enExample)
ZA (1) ZA202100955B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116735514B (zh) * 2023-08-11 2023-11-03 昆明理工大学 纳米酶结合液液微萃取快速检测天麻硫熏标志物的方法
WO2025184627A1 (en) * 2024-03-01 2025-09-04 Cadrenal Therapeutics, Inc. Method for preventing coagulation in patients with implanted cardiac devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145986A1 (en) * 2013-03-15 2014-09-18 Verseon, Inc. Multisubstituted aromatic compounds as serine protease inhibitors
WO2016044662A1 (en) * 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5579843A (en) 1994-08-16 1996-12-03 Loitherstein; Joel S. Resilient spider for well installation
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SI21097A (sl) 2001-12-04 2003-06-30 Univerza V Ljubljani Inhibitorji trombina
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
AR061996A1 (es) 2006-07-17 2008-08-10 Boehringer Ingelheim Int Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular
EA201100358A1 (ru) 2008-08-19 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Дабигатран для чрескожной хирургической катетеризации сердца
US20110190352A1 (en) 2008-08-19 2011-08-04 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
WO2010020601A1 (en) 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran in tumour therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145986A1 (en) * 2013-03-15 2014-09-18 Verseon, Inc. Multisubstituted aromatic compounds as serine protease inhibitors
WO2016044662A1 (en) * 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors

Also Published As

Publication number Publication date
CA3106359A1 (en) 2020-01-16
JP2025098029A (ja) 2025-07-01
US20210315877A1 (en) 2021-10-14
CN113164765B (zh) 2026-03-20
US11865110B2 (en) 2024-01-09
JP2021531338A (ja) 2021-11-18
IL280078B1 (en) 2023-12-01
IL280078A (en) 2021-03-01
WO2020014669A1 (en) 2020-01-16
BR112021000515A2 (pt) 2021-04-06
KR20210080347A (ko) 2021-06-30
AU2019300161A1 (en) 2021-02-25
EP3820564A1 (en) 2021-05-19
CN113164765A (zh) 2021-07-23
MX2021000472A (es) 2021-06-23
ZA202100955B (en) 2023-10-25
IL280078B2 (en) 2024-04-01
SG11202100247WA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
AU2021211993B2 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2017225000B2 (en) Multisubstituted aromatic compounds as serine protease inhibitors
JP2020143112A (ja) セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
JP6236445B2 (ja) 組織トランスグルタミナーゼ阻害剤としてのピリジノン誘導体
JP2025098029A (ja) トロンビン阻害薬、製剤、及びそれらの使用
EP1389194A2 (en) Inhibitors of bace
KR20130053404A (ko) 트롬빈 억제제로서의 다중치환된 방향족 화합물
JP2018506563A (ja) セリンプロテアーゼ阻害剤としての置換ピラゾール化合物
KR20050100655A (ko) 티에노〔2,3-ｃ〕피리딘 유도체를 함유하는 약제학적조성물 및 그의 용도
TW200911787A (en) New aza-bicyclohexane compounds useful as inhibitors of thrombin
JP2009501187A (ja) 新規なヘテロアリール縮合環式アミン
US9951025B2 (en) Halogenopyrazoles as inhibitors of thrombin
WO2007121662A1 (en) Diphenyl urea derivatives as kinase inhibitors, compositions and uses thereof
CN101486701B (zh) 色满酮类化合物及其类似物和医药用途
CN112778273B (zh) 环酮并吡啶酮类化合物及其制备方法和用途
CA3203896A1 (en) Plasmin inhibitor, and preparation method therefor and application thereof
EP4011880A1 (en) Jak kinase inhibitor and use thereof
CA2889538A1 (en) 1h-indole-3-carboxamide derivatives, and use thereof as p2y12 antagonists
CN102924442B (zh) 含有噻唑环的色满类化合物及其类似物和医药用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)